Immunovative Therapies Updated July 2013 Immunovative Therapies Receives $300,000 Grant From Misgav Venture.
AcceleratorImmunovative Therapies is developing unique and groundbreaking cancer treatments. The company’s founder and CEO, Dr. Michael Har-Noy has spent most of his career pioneering these novel new treatments. Because of the great promise of this work, Dr. Michael Har-Noy’s Immunovative Therapies was able to secure a $300,000 grant from the Misgav Venture Accelerator, a member of the Israel technological incubator program. The Misgav Venture Accelerator transforms brilliant life science ideas into great businesses, thereby facilitating scientific research and making significant improvements in the worlds of medicine and science.
Blackcat
